$22.84 -0.48 (-2.06%)
12/3/2009 4:00 PM

Abaxis, Inc. (ABAX)

CAPS Rating: 2 out of 5

The Company develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.

Current Price $22.84 Mkt Cap $502.98M
Open $23.48 P/E Ratio 39.53
Prev. Close $23.32 Div. (Yield) N/A (N/A)
Daily Range $22.80 - $23.60 Volume 63,471
52-Wk Range $12.93 - $29.80 Avg. Daily Vol. 175,000

ABAX News and Commentary

Related News and Articles

Caps

How do you think ABAX will perform vs the S&P 500?

Add Stock to Watchlist

All Members

141 Outperform
23 Underperform
 

All-Star Members

31 Outperform
7 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top ABAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bclan13 (99.40)
Submitted July 30, 2009

Animal health assets after Sanofi Merial buyout for 2X what the market was thinking it would be worth previously

brent2112 (< 20)
Submitted January 12, 2007

Abaxis has seen its glory days. I've watched this stock climb from $4-5 per share up to over $20. Unless they come up with something new, they will be relying on their reagent discs to supply income.

ABAX VS S&P 500 (SPY)

Fools bearish on ABAX are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about ABAX.

Recs

0
Member Avatar EclecticRecluse (75.12) Submitted: 11/5/2009 2:26:53 AM : Underperform Start Price: $23.14 ABAX Score: +5.76

Weakening Earnings Opinion

Recs

0
Member Avatar QwertyHero (38.43) Submitted: 9/4/2009 4:53:29 PM : Underperform Start Price: $26.67 ABAX Score: +22.04

BLUD is a much better play here. ABAX hs reached it's potential. There is not much room to move any higher. BLUD on the other hand has been beaten down like it stole something due to a recent FDA investigation which will likely not have any substantial effect on the company as it has spent 4 million to rectify issues identified by the FDA.

Recs

0
Member Avatar yooperking (91.95) Submitted: 9/3/2009 10:47:17 AM : Outperform Start Price: $26.07 ABAX Score: -23.24

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision
and accuracy equivalent to a clinical laboratory analyzer.
6/30/09 Quarterly highlights include:
-- Revenues of $29.6 million, up 21% over last year's comparable
quarter.
-- Veterinary market sales of $21.8 million, up 31% over last year's
comparable quarter.
-- North America revenues of $24.1 million, up 19% over last year's
comparable quarter.
-- International revenues of $5.5 million, up 29% over last year's
comparable quarter.
-- Medical and veterinary reagent disc sales of $18.4 million, up 31% over
last year's comparable quarter.
-- Gross profit of $17.2 million, up 27% over last year's comparable
quarter.
-- Operating income of $5.7 million, up 42% over last year's
comparable quarter.

-- Net income of $3.8 million, up 35% over last year's comparable
quarter.

Leaderboard

Find the members with the highest scoring picks in ABAX.

Score Leader

TheBarnacle

TheBarnacle (77.40) Score: +62.13

The Score Leader is the member with the highest score across all their picks in ABAX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
brightidea2006 < 20 7/30/2007 Outperform 3M $18.00 +26.89% -20.38% +47.27
hucktheduck < 20 8/2/2007 Outperform 3Y $18.44 +23.86% -20.97% +44.83
ugurmidtown 98.97 10/16/2008 Outperform NS $13.67 +67.08% +25.25% +41.83
alamobull < 20 1/26/2007 Outperform 3Y $18.72 +22.01% -17.83% +39.83 1 Comment
akakoolestkat < 20 7/13/2007 Outperform 3Y $19.94 +14.54% -24.83% +39.37 1 Comment
int38 56.87 1/16/2007 Outperform 5Y $19.00 +20.21% -18.09% +38.31
family56 75.44 1/3/2007 Outperform 3M $19.29 +18.40% -17.64% +36.04
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Cougarbob < 20 9/13/2007 Outperform NS $20.28 +12.62% -22.01% +34.64 1 Comment
caps123 24.58 1/8/2007 Outperform 3Y $19.40 +17.73% -16.79% +34.52
Zlobster 71.98 9/13/2007 Outperform 3Y $20.49 +11.47% -21.78% +33.25

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSunTrustRH 89.06 3/10/2009 Outperform NS $17.28 +40.91% +54.37% -13.45 10/13/2009 @ $24.35
TrackJimCramer < 20 1/17/2008 Underperform 3W $37.05 -38.35% -13.79% +24.57
TrackSunTrustRH 89.06 10/4/2007 Outperform NS $24.54 -22.66% -18.27% -4.39 7/25/2008 @ $18.98
TrackCLKing < 20 2/2/2007 Outperform NS $22.03 +3.68% -19.03% +22.71

Featured Broker Partners